NRAS and melanoma: Interestingly, there was a notable absence of the canonical melanoma BRAF/NRAS/NF1 driver mutations; instead, we detected a noncanonical BRAFV600D mutation that, although rare in melanoma (0.4% of cases), retains sensitivity to dabrafenib kinase inhibition in cell lines, implicating its role as an oncogenic driver (Gentilcore et al. 2013; Greaves et al. 2013).